ECONOMIC EVALUATION OF INFLIXIMAB AND ADALIMUMAB FOR CROHN'S DISEASE

被引：0
|
作者：
Hughes, D. A. [1 ]
Kikuchi, T. [1 ]
Bodger, K. [2 ]
机构：
[1] Bangor Univ, Bangor, Gwynedd, Wales
[2] Univ Liverpool, Liverpool L69 3BX, Merseyside, England
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)73358-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
下载
收藏
页码：A59 / A59
页数：1
相关论文
共 50 条
  • [21] Successful treatment with adalimumab in infliximab-resistant Crohn's disease
    Barthel, HR
    Gille, T
    Halbsguth, A
    Kramer, M
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10): : S121 - S121
  • [22] Response to Infliximab After Loss of Response to Adalimumab in Crohn's Disease
    Bauer, Christina M.
    Younis, Adam
    Herfarth, Hans
    Barnes, Edward L.
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (02) : E5 - E5
  • [23] Successful treatment with adalimumab in infliximab-resistant Crohn's disease
    Barthel, HR
    Gille, T
    Halbsguth, A
    Kramer, M
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 20 (09) : 1464 - 1465
  • [24] Infliximab vs. Adalimumab for Crohn's disease: authors' reply
    Kaplan, G. G.
    Hur, C.
    Korzenik, J.
    Sands, B. E.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (10) : 1266 - 1267
  • [25] Effects of Infliximab Retreatment After Consecutive Discontinuation of Infliximab and Adalimumab in Refractory Crohn's Disease
    Brandse, Johannan F.
    Peters, Charlotte P.
    Gecse, Krisztina B.
    Eshuis, Emma J.
    Jansen, Jeroen M.
    Tuynman, Hans A.
    Loewenberg, Mark
    Ponsioen, Cyriel Y.
    van den Brink, Gijs R.
    D'Haens, Geert R.
    INFLAMMATORY BOWEL DISEASES, 2014, 20 (02) : 251 - 258
  • [26] Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn's disease
    Carlsen, Arne
    Omdal, Roald
    Leitao, Kristian Ogreid
    Isaksen, Kjetil
    Hetta, Anne Kristine
    Karlsen, Lars Normann
    Aabakken, Lars
    Bolstad, Nils
    Warren, David
    Lundin, Knut E. A.
    Grimstad, Tore
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2018, 11
  • [27] Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn's disease
    Salar, Antonio
    Bessa, Xavier
    Muñiz, Eduard
    Monfort, David
    Besses, Carlos
    Andreu, Montserrat
    GUT, 2007, 56 (08) : 1169 - 1170
  • [28] Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study
    Zorzi, F.
    Zuzzi, S.
    Onali, S.
    Calabrese, E.
    Condino, G.
    Petruzziello, C.
    Ascolani, M.
    Pallone, F.
    Biancone, L.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (12) : 1397 - 1407
  • [29] Local Injection of Adalimumab for Perianal Crohn's Disease: Better Than Infliximab?
    Poggioli, G.
    Laureti, S.
    Pierangeli, F.
    Bazzi, P.
    Coscia, M.
    Gentilini, L.
    Gionchetti, P.
    Rizzello, F.
    INFLAMMATORY BOWEL DISEASES, 2010, 16 (10) : 1631 - 1631
  • [30] Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease
    Steenholdt, Casper
    Svenson, Morten
    Bendtzen, Klaus
    Thomsen, Ole Ostergaard
    Brynskov, Jorn
    Ainsworth, Mark Andrew
    JOURNAL OF CROHNS & COLITIS, 2012, 6 (01): : 108 - 111
12345